199105-16-3

Basic information

• Product Name: Piperazine, 1-(2-nitrophenyl)-4-(phenylmethyl)-
• CAS NO: 199105-16-3
• Molecular Formula: C17H19N3O2
• Molecular Weight: 297.357
• Mol File: 199105-16-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Piperazine, 1-(2-nitrophenyl)-4-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Piperazine, 1-(2-nitrophenyl)-4-(phenylmethyl)-(199105-16-3)
• EPA Substance Registry System: Piperazine, 1-(2-nitrophenyl)-4-(phenylmethyl)-(199105-16-3)

Safety Data

• Hazardous Substances Data: 199105-16-3(Hazardous Substances Data)

Upstream product

• 59084-06-9 1-(2-nitrophenyl)piperazine 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 2759-28-6 1-phenylmethylpiperazine 
• 88-73-3 2-Chloronitrobenzene 
• 1493-27-2 ortho-nitrofluorobenzene 

Downstream Products

• 508233-74-7 vortioxetine 
• 960203-27-4 Vortioxetine hydrobromide 
• 199105-19-6 1-(2-methanesulfonylamidophenyl)piperazine 
• 199105-18-5 N-[2-(4-Benzyl-piperazin-1-yl)-phenyl]-methanesulfonamide 
• 199105-17-4 2-(4-benzylpiperazin-1-yl)aniline 

Relevant articles and documents

PROCESS AND NOVEL POLYMORPHIC FORM OF VORTIOXETINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS

Processes are disclosed for making vortioxetine and pharmaceutically acceptable salts thereof. A propylene glycol solvate of vortioxetine hydrobromide is disclosed. A novel crystalline form of vortioxetine hydrobromide propylene glycol solvate, designated form AC1, is disclosed along with a method for making same. Form AC1 may be characterized by an x-ray powder diffraction pattern with peaks at about 19.64, 22.85, 25.51, 29.57, 30.18±0.2 degrees 2-theta.

Microwave-assisted aromatic nucleophilic substitution reaction of chloronitrobenzenes with amines in ionic liquids

An efficient method for aromatic nucleophilic substitution reaction of chloronitrobenzenes with several substituted amines in environmentally benign, 1-butyl-3-methylimidazolium tetrafluoroborate ionic liquid under microwave irradiation in reduced time period and high yields has been described.

Serine derived NK1 antagonists 2: A pharmacophore model for arylsulfonamide binding

Modifications to the spirocyclic aryl sulfonamide portion of serine derived NK1 antagonists allow a partial pharmacophore model to be developed.